

# A pharmaceutical company dedicated to treating aging and age-related disease

PITCH VIDEO INVESTOR PANEL



gerostatealpha.com San Francisco CA

Technology Life Science Bio Tech Moonshots Healthcare

OVERVIEW UPDATES 7 WHAT PEOPLE SAY 51 ASK A QUESTION 13

## Highlights

- 1 💰 \$2.1M raised in initial seed round, at \$15M valuation cap
- 2 🧑‍🔬 Team at the forefront of aging research for decades, collectively authoring 200+ papers
- 3 📈 Our platform delivers drug candidates to slow aging at a success rate of 20%
- 4 💰 Funds will be used to test 10-15 of our hits in aging mice
- 5 🏢 Executive chairman was former CEO of major pharma company, Sangamo Therapeutics

## Our Team



**Simon Melov** CEO

PhD; Professor at Buck Institute for Research on Aging & CEO of Gerostate Alpha

We know how to stop the threat of chronic disease; and we care because aging is 100% fatal



**Mark S Lucanic** CTO

PhD; Expert in small molecule and genetic screens including significant experience with high throughput technologies, and has utilized simple model organisms to explore pharmacological extension of lifespan.



**Gordon Lithgow** Professor, Vice President Buck Institute

PhD; Chief Academic Officer at the Buck Institute for Research on Aging and specializes in the properties of small molecules to extend lifespan, having been internationally recognized for his work on aging with numerous awards and prizes.

## Pitch




# Gerostate *Alpha*

We make drugs for Aging

## The Best Place in the World for an Aging Company

- Incubating at the Buck Institute for Research on Aging in Novato, CA
- Unique facilities and equipment for aging research
- World class expertise and research environment



Sunrise over the Buck Institute for Research on Aging



Gerostate *Alpha*

## Co-founders of Gerostate Alpha



**Simon Melov PhD**  
CEO



**Mark Lucanic PhD**  
CTO



**Gordon Lithgow PhD**  
Professor, Vice President  
Buck Institute

Forefront of aging research for decades  
200+ papers




Gerostate *Alpha*  
[www.gerostatealpha.com](http://www.gerostatealpha.com)

Raised more than \$90m in NIH  
and corporate sponsored research


## Edward Lanphier, former CEO Sangamo Therapeutics Gerostate *Alpha* Executive Chair

Solo founder of Sangamo Therapeutics  
Investor in Gerostate Alpha  
Led Sangamo for over 20 years  
Pioneered genome engineering as a therapeutic modality  
Multiple clinical trials  
Multiple pharma partnerships at Sangamo  
Led Sangamo to multi-billion dollar valuation





Gerostate Alpha  
www.gerostatealpha.com



Function declines with age from your 20's




Gerostate Alpha

## We want to Slow tissue aging




3 synergistic approaches: Novel interventions, FDA/EMA off-patent drugs, natural products



Gerostate Alpha


## State of the art deep phenotyping to determine efficacy of interventions

- Cardiovascular
- Bone
- Metabolic
- Neurological
- Pulmonary
- Muscular



Gerostate Alpha

## Unbiased drug development pipeline, addressing multiple functional domains of aging



Gerostate Alpha

Simultaneous pursuit of multiple preclinical indications reduces long term-risk

## Our platform delivers drug candidates to slow aging

- We screened 61,000 compounds for lifespan extension in our platform
- We have 30 hits which extend lifespan in our simple animal model
- We trialed 5 of these hits in aged mice for slowed aging
  - 6 month treatment from 20 months-26 months of age
  - 1 out of 5 resulted in measurable slowing of a major aging tissue (bone)

## OUR PLATFORM DELIVERS HITS AT 20% SUCCESS RATE!

### Milestones


- Trial 10-15 compounds in mice for lifespan extension and slowed aging over the next 12 months
- Lead optimization covering diverse/novel targets of aging; identify novel targets and pathways (12 months)
- Evaluate efficacy in preclinical diseases/syndromes (12-24 months), complete preclinical toxicology testing & pharmacokinetics
- IND enabling Phase 1 (24/36 months)



Gerostate *Alpha*

Disclaimer: This slide contains forward-looking projections that cannot be guaranteed

### Business development strategy



Gerostate *Alpha*

### Fundraising

\$2.1M raised in initial seed round, at \$15M valuation

\$2M current round (250K already committed, at \$15M post valuation)

We are super Capital efficient!

Funds will be used to test 10-15 of our hits in aging mice



Gerostate *Alpha*  
[www.gerostatealpha.com](http://www.gerostatealpha.com)

Raising up to \$1.07M on Wefunder

[Link to recorded Clubhouse pitch night on Startup Club](#)



"I've many years of investment experience across multiple sectors. The Gerostate alpha team is aiming for the stars, and are top innovators in their field. I'm hoping they succeed in their mission statement, I want to be a customer!"

**Rich Robbins**

CEO, Wareham Development

Two-time Investor!